Showing 1 - 10 of 309
This paper examines why physicians continue to prescribe trade- name drugs when less expensive generic substitutes are available. I utilize a data set on physicians, their patients, and the multi-source drugs prescribed to study the prescription habits of physicians in prescribing generic and...
Persistent link: https://www.econbiz.de/10013247652
Empirical studies suggest that entry of generic competitors results in minimal decreases or even increases in brand …-name drug prices as well as sharp declines in brand-name advertising. This paper examines circumstances under which this … empirical pattern could be observed. The analysis focuses on models where the demand for brand-name pharmaceuticals is divided …
Persistent link: https://www.econbiz.de/10013226930
pharmaceutical product sales data for India with a newly gathered dataset of molecule-linked patents issued by the Indian patent … office. Exploiting variation in the timing of patent decisions, we estimate that a molecule receiving a patent experienced an … by just one firm when the patent system began. Our results also show little impact on quantities sold or on the number of …
Persistent link: https://www.econbiz.de/10013046165
consumption effects, e.g. the analysis of the welfare effects of patent regulations. This paper analyzes the joint problem of the …
Persistent link: https://www.econbiz.de/10013237532
This paper studies how patent rights and price regulation affect how fast new drugs are launched in different countries … duration and content of patent and price control regimes. Price regulation strongly delays launch, while longer and more … extensive patent protection accelerates it. Health policy institutions, and economic and demographic factors that make markets …
Persistent link: https://www.econbiz.de/10013032477
patent rights on branded prescription drugs are eliminated for both existing and future prescription drugs without … compensation to the patent holders. The question of whether this policy maximizes consumer welfare cannot be resolved on an a …
Persistent link: https://www.econbiz.de/10013212342
The pricing of medical products and services in the U.S. is notoriously complex. In health care, supply prices (those received by the manufacturer) are distinct from demand prices (those paid by the patient) due to health insurance. The insurer, in designing the benefit, decides what prices...
Persistent link: https://www.econbiz.de/10013128277
In this survey chapter on pricing and reimbursement in U.S. pharmaceutical markets, we first provide background information on important federal legislation, institutional details regarding distribution channel logistics, definitions of alternative price measures, related historical...
Persistent link: https://www.econbiz.de/10013139118
affects prices to retail pharmacies, plausibly because uncertain quality leads to competition on brand rather than price …
Persistent link: https://www.econbiz.de/10013122879
The extent of pharmaceutical advertising and promotion can be characterized by a balancing act between profitable demand expansions and potentially unfavorable subsequent regulatory actions. However, this balance also depends on the nature of competition (e.g. monopoly versus oligopoly). In this...
Persistent link: https://www.econbiz.de/10013123314